A post hoc analysis shows significantly improved ORR and PFS in advanced NSCLC with higher AFM24 exposure, supporting ...

A new drug application seeking the approval of ziftomenib was submitted to the FDA on April 8, 2025. This indication is for ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

INX-315, a CDK2 inhibitor, gained FDA fast track status in CCNE1-positive platinum-resistant/refractory ovarian cancer.

Ahmad Abuhelwa, MD, discusses the mechanisms of statins and how they can play a surprisingly beneficial role in patients with chronic lymphocytic leukemia.

During a live event, Ahmad Tarhini, MD, PhD, discussed key melanoma trials with varying survival and toxicity profiles.

Following clearance from the FDA, a phase 1/2 study will assess OBI-902 in Trop-2-overexpressing solid tumors, with plans for ...

Olalekan O Oluwole, MD, MBBS, discussed a study on cytokine release syndrome and neurological events post axicabtagene ...

In interviews with Targeted Oncology, Ronan J. Kelly, MD, MBA, and David Zhen, MD, discuss the CheckMate 649 trial of ...

During a live event, Naresh Bumma, MD, discussed talquetamab’s efficacy in relapsed/refractory multiple myeloma, including ...

Ravindra Uppaluri, MD, PhD, discussed the KEYNOTE-689 trial, which investigated pembrolizumab in locally advanced head and ...

An expert discusses how addressing unmet needs in early diagnosis, treatment options, and long-term management, alongside ...